InventroS.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2023-02-08
Share capital
100 165,00 PLN
Activity description

Inventro is a company that explores the complexities of cellular functioning by integrating in-vitro cell-based assays with machine learning and artificial intelligence. They focus on drug development and personalized medicine, utilizing sophisticated data analysis alongside wet-lab experimentation. Their team includes experts in computational methodologies, cell biology, and biochemistry, driving innovation in scientific research.

Registered address
ul. Złota 2/19, 15-016 Białystok, Poland
Website
inventro.coWebsite active
Electronic delivery address
AE:PL-61488-48693-TEEJU-18

Financials

The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 12.18kMedianUSD 38.31kAverageUSD 2.31m
Net profit
This companyUSD -44.14kMedianUSD -1.50kAverageUSD -84.98k
Operating costs
This companyUSD 45.25kMedianUSD 56.25kAverageUSD 2.29m
Assets
This companyUSD 260.23kMedianUSD 116.77kAverageUSD 2.72m

News

Cell death

Cell death

Cell-death assays are crucial tools for drug discovery and development, providing insights into the mechanisms of programmed cell death and drug-induced cell death. By using these assays, researchers can assess the efficacy and safety of potential drug candidates, optimize drug dosages, and identify potential adverse effects. There are several types of cell death, including apoptosis,

Cell health assays

Cell health assays

Cell health assays measure various cellular processes to provide insight into how and why cells proliferate or die. These are primary tools to assess the cytotoxicity of drug candidates or other compounds, analyze cellular parameters in various diseases including cancer, and study basic cellular processes. The selection of a specific cell health assay depends on

Cell toxicity

Cell toxicity

One of the main events that occur after cell death is the loss of membrane integrity, which allows chemicals or proteins to freely enter or exit the cell. Taking advantage of this phenomenon, we are able to evaluate the cytotoxicity of a given compound either by determining the exact number of dead cells stained with

Protein target prediction

Protein target prediction

Protein target prediction is a critical component of modern drug design and pharmaceutical research. Computational methods provide fast and cost efficient solutions for obtaining initial hypotheses in areas such as virtual screening, drug repurposing or side effects prediction. Their predictive value constantly increases, benefitting from exponential growth of available data and computer power. Currently, given

Protein targets

Protein targets

Our AI-driven model for protein target prediction is designed to support the fast-paced environment of drug discovery. Our model streamlines the prediction of compound activities across a broad spectrum of protein targets, enhancing the efficiency of virtual assays and screening processes. By facilitating the rapid evaluation of millions of compounds, it offers a significant advantage

Virtual assays - new service by Inventro

Virtual assays - new service by Inventro

Responses from individual targets are grouped according to target class into virtual assays panels that mirror those widely used in in-vitro screening assays. For each compound they provide instant information concerning possible area of application, off-target prediction, as well as potential safety concerns. Protein kinases Kinase binding assays play a crucial role in drug design,

Bank accounts

Registered as a VAT taxpayer on 2023-03-01. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

PurposeGross amount
Aid for research and development projects: industrial research
—
Aid for research and development projects: experimental development
—

European Funds

ProjectEU co-financing
Wysokoprzepustowa i wieloparametrowa platforma dla testowania kandydatów na leki i leków przy użyciu modeli nowotworów ex vivo
$2.1M

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Tomasz Piotr Nowowiejski — President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board is authorised independently to represent the company. In the case of a multi-member management board being appointed, joint action of two members of the management board or one member of the management board jointly with a commercial proxy is required to represent the company.

Supervisory board

Beata Szukajt — Supervisory Board Member
Mariusz Grotek — Supervisory Board Member
Monika Szamborska — Supervisory Board Member

Beneficial owners

Person
Michał Komorowski (46)
Tomasz Piotr Nowowiejski (57)

Competitors

Name
Biostat Research and Developmentsp. z o.o.
Zawamedsp. z o.o.
Orphinic ScientificS.A.
CannamedaiS.A.
Medaisp. z o.o.
Detoxedsp. z o.o.
Instytut Produktusp. z o.o.
AI4Isp. z o.o.
IncellvuS.A.
Fusiomicasp. z o.o.

Change history

DateEvent
2026-09-17Share capital change
2026-08-07Address change
2023-03-02PKD change
2023-02-08Entered in the register

FAQ

Last updated: 2026-10-03